June is shaping up to be a pivotal month for shareholders of Neos Therapeutics (NASDAQ: NEOS) and Portola Pharmaceuticals (NASDAQ: PTLA). Neos is gearing up for the potential launch of their second-ever product, while Portola is awaiting the early anticipated ruling from the FDA on its next-generation anticoagulant. For more on what these moves could mean for these companies, it’s time for a deeper dive.